<DOC>
	<DOCNO>NCT00748566</DOCNO>
	<brief_summary>The purpose study explore impact ziprasidone distribution metabolic syndrome risk factor population patient present glucose intolerance , dyslipidemia and/or elevate waist circumference associate current antipsychotic medication .</brief_summary>
	<brief_title>One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome</brief_title>
	<detailed_description>The trial terminate prematurely May 24 , 2012 , due change organizational strategy resource . The decision terminate trial base safety efficacy concern .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Schizophrenia Spectrum Other Psychotic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Subject must present least 2 follow risk factor MS screening : Elevated waist circumference : &gt; 102 cm men &gt; 88 cm woman ; Elevated triglyceride ( TGs ) : ≥1.7 mmol/L ( ≥150 mg/dL ) ; Reduced HDLCholesterol : &lt; 1.03 mmol/L ( &lt; 40 mg/dL ) men &lt; 1.3 mmol/L ( &lt; 50 mg/dL ) woman ; Elevated fast glucose : ≥ 5.6 mmol/L . According clinical judgment investigator , risk factor MS develop close temporal relationship start antipsychotic medication . Substitution less metabolically disruptive antipsychotic medication consider . Subjects contraindication ( ) use Ziprasidone accord Canadian prescribing information . Subjects history treatment resistance . Subjects medical condition ( e.g . preexist diabetes , preexist dyslipidemia , thyroid pathology ) take concomitant medication ( e.g . topiramate weight losspromoting agent , hypoglycemic agent , hypolipemic agent ) , may confound evaluation study drug . Body mass index ≥ 40 baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Ziprasidone</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>risk factor</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>psychotic disorder .</keyword>
</DOC>